{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:29:31Z","timestamp":1789010971843,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01279","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T08:12:05Z","timestamp":1542096725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS\/AML"],"prefix":"10.3389","volume":"9","author":[{"given":"Daniel","family":"Heudobler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Klobuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00277-001-0412-9","article-title":"A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis","volume":"81","author":"Agis","year":"2002","journal-title":"Ann. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst","year":"2011","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ncb3625","article-title":"Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche","volume":"19","author":"Boyd","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1309\/AJCP6GR8BDEXPKHR","article-title":"An updated approach to the diagnosis of myeloid leukemia cutis","volume":"132","author":"Cronin","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2012.47","article-title":"5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity","volume":"26","author":"Curik","year":"2012","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1172\/JCI64745","article-title":"CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR\u03b3 signaling","volume":"123","author":"Faber","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/jdv.13391","article-title":"Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial","volume":"30","author":"Hart","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12307-015-0170-1","article-title":"Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from chemorefractory Neoplasia","volume":"8","author":"Hart","year":"2015","journal-title":"Cancer Microenviron."},{"key":"B10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0190-9622(99)70086-1","article-title":"Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria","volume":"40","author":"Kaddu","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1590\/abd1806-4841.20186327","article-title":"Clinical and pathological features of myeloid leukemia cutis","volume":"93","author":"Li","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MOH.0000000000000400","article-title":"Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes","volume":"25","author":"Montalban-Bravo","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-4632.2011.05297.x","article-title":"Myeloid leukemia cutis in the setting of myelodysplastic syndrome: a crucial dermatological diagnosis","volume":"51","author":"Patel","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1046\/j.1468-3083.2001.00231.x","article-title":"Skin involvement in chronic myelomonocytic leukaemia as a predictor of transformation into acute myeloid leukaemia","volume":"15","author":"Pont","year":"2001","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12307-008-0012-5","article-title":"Systems biology: a therapeutic target for tumor therapy","volume":"1","author":"Reichle","year":"2008","journal-title":"Cancer Microenviron."},{"key":"B16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2018.01.020","article-title":"Anti-leukemic effects of PPAR\u03b3 ligands","volume":"418","author":"Ryu","year":"2018","journal-title":"Cancer Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ijo.29.2.437","article-title":"Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells","volume":"29","author":"Saiki","year":"2006","journal-title":"Int. J. Oncol."},{"key":"B18","first-page":"223","article-title":"Clinical, histopathologic, and immunohistochemical correlations in leukemia cutis","volume":"13","author":"Su","year":"1994","journal-title":"Semin. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"483656","DOI":"10.1155\/2012\/483656","article-title":"Effects of PPAR\u03b3 ligands on leukemia","volume":"2012","author":"Tabe","year":"2012","journal-title":"PPAR Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.3324\/haematol.2014.115055","article-title":"Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia","volume":"100","author":"Thomas","year":"2015","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199310000-00006","article-title":"Extramedullary myeloid cell tumors. An immunohistochemical and morphologic study of 28 cases","volume":"17","author":"Traweek","year":"1993","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T08:12:07Z","timestamp":1542096727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":21,"alternative-id":["10.3389\/fphar.2018.01279"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01279","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"article-number":"1279"}}